Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humatrope for short stature

Executive Summary

Lilly's growth hormone Humatrope (somatropin, rDNA origin) approved by FDA for idiopathic short stature July 25. Lilly will not conduct DTC advertising for Humatrope, will market the new indication only to pediatric endocrinologists and will distribute the product through controlled channels, as discussed during FDA's Endocrinologic & Metabolic Drugs Advisory Committee's June 10 review (1"The Pink Sheet" June 16, 2003, p. 28)...
Advertisement

Related Content

Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
Lilly Humatrope Risk Plan Relies On Limited Promos; Cmte. Wants Registry
Lilly Humatrope Risk Plan Relies On Limited Promos; Cmte. Wants Registry
Advertisement
UsernamePublicRestriction

Register

PS042198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel